All Posts

July 2026 QQ: VWD Therapeutic

We commemorate the 1926 publication by Finnish physician, Eric von Willebrand, Von Willebrand, E A (1926). “Hereditär pseudohemofili”. Finska Läkaresällskapets Handlingar (in Swedish). 68: 87–112. Dr. von Willebrand’s title, “Hereditary Pseudohemophilia,” was updated to our current name, von Willebrand disease, in the late 1930s, and the responsible protein was named von Willebrand factor in 1971. […]

Bleeding Disorders

External Quality Assessment for Anti-FXa LMWH Assays

Check with your local medical library for this thought-provoking article: Favaloro EJ, Arunachalam S, Pasalic L. External quality assessment for low molecular weight heparin monitoring in the Australasia/Asia-Pacific region. Semin Thromb Hemost. 2026. doi: 10.1055/a-2900-7026. Epub ahead of print. PMID: 42398957. Abstract LMWH remains a widely used parenteral anticoagulant in hospital and outpatient settings for […]

Anticoagulant Therapy

What is Anticoagulation Drift?

Click to read this LinkedIn post, where Edward Lee Carter, BSPharm, CPP, states: “The greatest threat to long-term anticoagulation may not be choosing the wrong drug. It may be failing to recognize that the patient has changed.” He illustrates the value of clinical laboratory assays to periodically confirm DOAC dosages.

Anticoagulant Therapy

Why Does Blood Group O Reduce VWF?

Dr. Abdul Mannan’s LinkedIn post, “Why Does Blood Group O Reduce VWF?” presents the physiology of VWF in blood group O.

Bleeding Disorders

Are we Overusing LMWH?

A provocative open-access article posted on LinkedIn by Dr. Emmanuel Favaloro suggesting we are overusing LMWH: Gurumurthy G, Fan B, Gurumurthy J, et al. Should we focus on sustainable thromboprophylaxis and avoid overuse of low-molecular-weight heparins? Research and Practice in Thrombosis and Haemostasis, 2026; 10. DOI: 10.1016/j.rpth.2026.106794. Abstract Low-molecular-weight heparins (LMWHs) have become a near-routine prescription […]

Anticoagulant Therapy

Why Clotting Patients Bleed

Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared a column, Why Clotting Patients Bleed, in Hemostasis Today.

DOAC Monitoring–What to Order

Ifeanyichukwu Ifechidere, Specialist Biomedical Scientist at Sheffield Teaching Hospital NHS Foundation Trust, shared her column, DOAC Monitoring–What to Order, When, and Why in Hemostasis Today.

Anticoagulant Therapy

July 2026 Cheat Sheet

Click the Cheat Sheet for your July 2026 edition. You can also request your personal Cheat Sheet with links to recent Fritsma Factor entries by completing the “Sign Up” entry on the right. Fritsma Factor, Educational Modules, and Resources are provided compliments of Precision BioLogic Inc.

June 2026 QQ Review: VWF Gain of Function

Our June 2026 QQ, which drew 30 responses, asked, “What VWD subtype is caused by a VWF gain of function?” Here are your responses: VWD type 1: 3 (10%) VWD subtype 2A: 1 (3%) VWD subtype 2B: 24 (80%) VWD subtype 2M: 2 (7%) VWD subtype 2N: 0 VWD type 1 is the quantitative form […]

Bleeding Disorders

A New Era in VWD Treatment

Click here for an informative LinkedIn/Hemostasis Today post from Shadi Tabibian, Deputy of Research at Blood Diseases Research Centers in Iran University of Medical Sciences, A New Era in VWD Treatment. For decades, the management of VWD has relied mainly on VWF concentrates, desmopressin, antifibrinolytic agents, and hormonal therapies. Although these treatments remain effective for […]

Bleeding Disorders

Load more

George Fritsma is a medical laboratory scientist, educator, and author. George is a member of the International Society on Thrombosis and Hemostasis, the International Society for Laboratory Hematology, and the American Society for Clinical Laboratory Science.

Cheat Sheets from George

Quick Question